TP53 and cancer: Specifically, cancer cells with a gain‐of‐function p53‐mutant educated a dominant CAF cohort for a pro‐metastatic microenvironment that delayed cancer cell response to gemcitabine/abraxane, and reprogrammed the rest CAF populations towards the acquisition of more invasive features.225